Secondly, the size of subjects in this study may not sufficiently large to explore the association between PNPLA3 I148M and TM6SF2 E167K with the risk of CHD in NAFLD patients. The gene discussed is TM6SF2; the disease is metabolic dysfunction-associated steatotic liver disease.